WO2017096617A1 - Trousse de réactif pour culture étape par étape de huc-msc et huc-msc acquises au moyen dudit kit de réactif - Google Patents

Trousse de réactif pour culture étape par étape de huc-msc et huc-msc acquises au moyen dudit kit de réactif Download PDF

Info

Publication number
WO2017096617A1
WO2017096617A1 PCT/CN2015/097150 CN2015097150W WO2017096617A1 WO 2017096617 A1 WO2017096617 A1 WO 2017096617A1 CN 2015097150 W CN2015097150 W CN 2015097150W WO 2017096617 A1 WO2017096617 A1 WO 2017096617A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
medium
huc
volume
msc
Prior art date
Application number
PCT/CN2015/097150
Other languages
English (en)
Chinese (zh)
Inventor
郭镭
Original Assignee
郭镭
里程
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 郭镭, 里程 filed Critical 郭镭
Priority to US16/061,272 priority Critical patent/US11091739B2/en
Priority to PCT/CN2015/097150 priority patent/WO2017096617A1/fr
Publication of WO2017096617A1 publication Critical patent/WO2017096617A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1369—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood

Definitions

  • the invention relates to the research field of stem cells, in particular to a novel and high-efficiency serum-free stepwise culture kit for hUC-MSC.
  • Mesenchymal stem cells are ubiquitous in various tissues and organs of human body, and have multi-directional differentiation potential. They have functions of stimulating tissue regeneration and regulating immunity, and have broad application prospects in the field of cell therapy.
  • hUC-MSC Human Umbilical Cord mesenchymal stem cells derived from human umbilical cord express unique markers of various embryonic stem cells, have large differentiation potential, strong proliferative ability, low immunogenicity, and convenient materials. , no restrictions on ethical issues, easy to industrialize and other characteristics, and studies have confirmed that hUC-MSC has good therapeutic effects in animal models and clinical studies of diseases such as neurological diseases, immune system, endocrine system, cancer, heart disease, etc. It may become the most versatile stem cell for clinical application.
  • hUC-MSC In order to further apply hUC-MSC to clinical practice, the most important thing is that the large-scale expansion of hUC-MSC in vitro reaches an effective clinical therapeutic dose. Therefore, in vitro culture of hUC-MSC has become one of the most basic and most important technologies.
  • Existing hUC-MSC culture methods mostly use FBS and streptomycin in the basal medium, but the non-human serum components are complex, which makes hUC-MSCs easy to differentiate during long-term culture, and there is no non-existing pathogens. Danger.
  • Another object of the present invention is to provide hUC-MSC obtained by the medium of the present invention.
  • the present invention provides a novel kit culture protocol for serum-free stepwise culture of hUC-MSC, the kit comprising at least two culture media of different compositions, and the medium in the kit can be used in serum-free
  • the stepwise culture and long-term expansion culture of hUC-MSC were carried out under the environment, and at the same time, it was ensured that it maintained pluripotency and strong proliferative ability under long-term culture.
  • the invention provides a kit for stepwise culturing hUC-MSC, the kit comprising separately placed TME medium and TMD medium. Both media were serum free and used for stepwise culture of hUC-MSCs.
  • the hUC-MSC is a human umbilical cord mesenchymal stem cell isolated from a healthy neonatal umbilical cord tissue that is naturally delivered or cesarean section.
  • a human umbilical cord mesenchymal stem cell isolated from a healthy neonatal umbilical cord tissue that is naturally delivered or cesarean section.
  • the TME medium comprises a-MEM, ⁇ -mercaptoethanol, and non-essential amino acids.
  • the TME medium contains 0.05-0.2 parts by volume of ⁇ -mercaptoethanol, 0.5-2 parts by volume of an aqueous solution of non-essential amino acids, and 95-100 parts by volume of a-MEM, wherein the non-essential amino acid aqueous solution comprises The concentration is 8-12 mM each of glycine, alanine, L-tianmenamide, L-aspartic acid, glutamic acid, proline and serine; more preferably, the TME medium contains 0.1 part by volume of ⁇ - mercaptoethanol, 1 part by volume of a non-essential amino acid aqueous solution and 99 parts by volume of a-MEM; further preferably, the TME medium consists of the a-MEM, ?-mercaptoethanol and a non-essential amino acid aqueous solution.
  • the TMD medium contains a-MEM/DMEM-F12, ⁇ -mercaptoethanol, non-essential amino acids, recombinant human basic fibroblast growth factor (b-FGF), and serum substitute.
  • the TMD medium comprises 0.05-0.2 parts by volume of ⁇ -mercaptoethanol, 0.5-2 a volume of aqueous solution of non-essential amino acids, 8-12 parts by volume of serum replacement, 85-95 parts by volume of a-MEM/DMEM-F12, and recombinant human basic fibroblast growth factor at a final concentration of 5-15 ng/ml
  • the non-essential amino acid aqueous solution comprises glycine, alanine, L-aspartamide, L-aspartic acid, glutamic acid, proline and serine at a concentration of 8-12 mM each; more preferably, said The TMD medium contains 0.1 parts by volume of ⁇ -mercaptoethanol, 1 part by volume of an aqueous solution of non-essential amino acids, 10 parts by volume of serum substitute, 89 parts by volume of a-MEM/DMEM-F12, and a final concentration of 10 ng/ml.
  • the TMD medium consists of the a-MEM/DMEM-F12, ⁇ -mercaptoethanol, an aqueous solution of a non-essential amino acid, a recombinant human basic fibroblast growth factor, and a serum substitute.
  • the non-essential amino acid aqueous solution may be a product of Gibco Corporation No. 11140.
  • the serum replacement may be used KnockOut TM Serum Replacement (Gibco Products, Catalog No. 10828-010).
  • the hUC-MSC can be cultured stepwise using the kit of the present invention, and the culture method comprises first culturing hUC-MSC using the TME medium in the kit, and then culturing using the TMD medium in the kit. That is, two culture media are used for culture;
  • the culture method comprises the following steps:
  • the hUC-MSC cells collected in step (3) are taken to detect one or more of the following items: differentiation ability, cell activity, cell purity, cell contamination, and proliferation characteristics.
  • the culture method comprises the following steps:
  • the hUC-MSC cells collected in step (3) were taken to detect all of the following items: differentiation ability, cell activity, cell purity, cell contamination, and proliferation characteristics.
  • the serum-free stepwise culture method for hUC-MSC comprises the following steps:
  • the following items were examined: differentiation ability, cell activity, cell purity, cell contamination, and proliferation characteristics.
  • the present invention also provides hUC-MSC obtained by the above method.
  • the hUC-MSC has the following characteristics:
  • the present invention also provides a TME medium and/or a TMD medium used in the above culture method.
  • the TME medium and the TMD medium in the kit of the present invention are serum-free components, and the composition is clear, thereby avoiding cells caused by serum batch differences in the culture of the cultured cells.
  • the unstable growth process also precludes the possibility of spreading heterologous pathogens.
  • the TME medium was first cultured to promote hUC-MSC adherence, and then replaced with TMD medium for rapid amplification, which solved the conventional serum-free culture.
  • the cells have poor adherence ability and slow proliferation, and the cells can maintain good proliferation ability and multi-directional differentiation potential during long-term culture, which provides an efficient solution for in vitro culture of animal cells.
  • kit of the present invention is simple to operate and shortens the primary culture time.
  • the mesenchymal stem cells obtained by the method of the invention have high activity, high purity and strong differentiation ability, and the established cell bank can be directly used for Scientific research and clinical adjuvant therapy.
  • Fig. 1 is a diagram showing the culture of hUC-MSCs using a serum-containing medium, wherein Fig. 1A shows the morphology of cells after inoculation for 2 hours, Fig. 1B shows the morphology of cells after 24 hours of inoculation, and Fig. 1C shows the morphology of cells after 48 hours of inoculation.
  • Figure 2 is a cell diagram during the screening of the medium composition, wherein Figure 2A shows the cell morphology of the high-concentration ⁇ -mercaptoethanol medium after 4 hours of cell inoculation, and Figure 2B shows the cells after 48 hours of inoculation with the low-concentration serum replacement medium. Morphology, Fig. 2C shows the morphology of the cells after inoculation for 24 hours in the high-concentration serum replacement medium, Fig. 2D shows the morphology of the cells after inoculation for 24 hours in the low-concentration bFGF medium, and Fig. 2E shows the morphology of the cells in the high-concentration bFGF medium after passage.
  • Figure 3 is a diagram showing the culture of hUC-MSCs using the TME medium in the kit, wherein Figure 3A shows the cell morphology after 2 hours of inoculation, Figure 3B shows the cell morphology after 24 hours of inoculation, and Figure 3C shows the cells after 48 hours of inoculation. form.
  • Figure 4 is a diagram showing the culture of hUC-MSCs using the TMD medium in the kit, wherein Figure 4A shows the cell morphology after 2 hours of inoculation, Figure 4B shows the cell morphology after 24 hours of inoculation, and Figure 4C shows the cells after 48 hours of inoculation. form.
  • Figure 5 is a diagram showing the stepwise culture of hUC-MSC using the kit of the present invention, wherein Figure 5A shows the cell morphology after inoculation with TME medium in the kit for 2 hours, and Figure 5B shows the reagent used.
  • the TME medium in the cassette was replaced with TMD medium for 4 hours and then cultured for 24 hours.
  • Figure 5C was inoculated with TME medium in the kit for 4 hours and then changed to TMD medium for further 48 hours. Cell morphology.
  • Figure 6 shows the results of analyzing cell surface molecules by flow cytometry of hUC-MSC obtained by serum-free stepwise culture in the kit of the present invention, showing that the hUC-MSC expresses CD29, CD44, The positive proportion of CD73, CD90, CD105 and HLA-ABC was greater than 99%; the positive proportion of CD45, CD34 and HLA-DR was less than 1%.
  • Fig. 7 is a result of analyzing the cell viability and growth characteristics of the obtained hUC-MSC by Vi-Cell cell viability analyzer, wherein Fig. 7A is a diameter distribution map of hUC-MSC, and Fig. 7B is a growth curve of hUC-MSC, and Fig. 7C is a growth curve of hUC-MSC.
  • the real-time viability analysis of hUC-MSC showed that the hUC-MSC activity was above 99.7%, the cell diameter was around 13 ⁇ m, and it had the proliferation characteristics of latency, logarithmic growth and plateau.
  • Figure 8 is a result of the induced differentiation of hUC-MSCs obtained into osteoblasts and osteoblasts, wherein Fig. 8A shows a dark red compound produced by the color reaction of alizarin red with the calcium nodules of the osteogenesis process. 8B shows the fat bubble-specific coloration of oil red O to adipocytes.
  • Figure 9 shows the hUC-MSC pluripotency-specific protein obtained by immunofluorescence staining, from left to right, from top to bottom, SSEA-4, SOX-2, OCT-4, and NANOG.
  • Test medium 89 parts by volume of ⁇ -MEM, 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 U/ml streptomycin, 0.1 part by volume of ⁇ -mercaptoethanol, 10 ng/ml of b-FGF 1 part by volume of an aqueous solution of a non-essential amino acid (11140, Gibco).
  • FBS fetal bovine serum
  • penicillin 100 U/ml
  • streptomycin 100 U/ml streptomycin
  • 0.1 part by volume of ⁇ -mercaptoethanol 10 ng/ml of b-FGF 1 part by volume of an aqueous solution of a non-essential amino acid (11140, Gibco).
  • the 3rd generation hUC-MSC isolated from the natural umbilical cord of the newborn baby was inoculated into the T75 cell culture flask at a density of 2 ⁇ 10 4 cells/cm 2 and 15 mL was added.
  • the medium was transferred to a 37 ° C incubator with a CO 2 concentration of 5%. After 2 hours of inoculation, the adherence of the cells was observed. A large number of cells of hUC-MSC adhered to the cells and extended tentacles; after 48 hours, hUC-MSCs reached 90% confluence; the cells were stretched and bright.
  • Example 1 cells were inoculated at the same cell source and at the same density, and 15 mL of a commercially available serum-free medium (product of Saiye Co., Ltd., product number HUXUC-90061) was added to culture the cells. After inoculation for 2 hours, the cells were attached, the cells were bright, mostly round, and the antennae were stretched. After 24 hours of inoculation, the cells were observed.
  • a commercially available serum-free medium product of Saiye Co., Ltd., product number HUXUC-90061
  • the hUC-MSC was bright under the microscope, and the antenna extended, and the amplification was not obvious; After that, the cell confluence rate was about 50%; after 72 hours of inoculation, the cells were observed, and the hUC-MSC cells were bright, reaching more than 90% confluence, and the cells were cryopreserved by trypsin digestion.
  • the cells After the cells reach 100% confluence, after continuing the culture, the cells begin to curl off from the edge of the culture flask. From this, it can be seen that when the serum component is lacking, the cells are easily detached, and it is difficult to maintain a good adherence state.
  • Test medium 0.01, 0.02, 0.05, 0.1, 0.15, 0.2, 0.3 or 0.5 parts by volume of ⁇ -mercaptoethanol, 1 part by volume of aqueous solution of non-essential amino acids (11140, Gibco), 99 parts by volume of a-MEM .
  • Example 1 cells were seeded at the same density with the same cell source, and 15 mL of the test medium was added to culture the cells. Observe the cell adherence.
  • TME medium 0.1 part by volume of ⁇ -mercaptoethanol, 1 part by volume of an aqueous solution of non-essential amino acids (11140, Gibco), 99 parts by volume of a-MEM.
  • Test medium 0.1 part by volume of ⁇ -mercaptoethanol, 10 ng/ml of recombinant human basic fibroblast growth factor (b-FGF, Peprotech), 1 part by volume of aqueous solution of non-essential amino acids (11140, Gibco), 1, 2, 5, 8, 10, 12, 15 or 20 parts by volume of Knockout FBS serum replacement (10828-028, Gibco), 89 parts by volume of a-MEM.
  • Example 1 cells were seeded at the same density with the same cell source, and 15 mL of TME medium was added. Two hours after the inoculation, the cells were observed to adhere to the cells, and the culture was continued. After about 4 hours of inoculation, the cells were completely adhered, and 15 mL of the test medium was replaced. Observe the growth of the cells.
  • RESULTS In the three concentration groups containing 1, 2, and 5 volumes of serum substitutes in the medium, the cells proliferated slowly. After 24 hours of inoculation, the cells were observed. Some cells of hUC-MSC aggregated, the cells were flat, and the refractive index was poor. The confluence reached about 20%. After 48 hours of inoculation, the cells were observed. The hUC-MSC cells were bright, and after about 60% confluence, the proliferation was basically stopped (see Figure 2B); in the medium, there were 8, 10, and 12 volumes, respectively. In the three concentration groups of serum substitutes, the cells grew well. After 24 hours of inoculation, the cells were observed.
  • the hUC-MSCs were spindle-shaped and vortex-like, with high elongation and bright cells, and the confluence reached 40-60%. After the hour, the cells were observed, hUC-MSC cells were bright, reaching more than 90% confluence; in the two concentration groups containing 15 and 20 volumes of serum substitutes in the medium, the same condition as in the low concentration group occurred, and the cells grew slowly. The cells are flattened and the outline is clear (see Figure 2C).
  • TME medium 0.1 part by volume of ⁇ -mercaptoethanol, 1 part by volume of an aqueous solution of non-essential amino acids (11140, Gibco), 99 parts by volume of a-MEM.
  • Test medium 0.1 part by volume of ⁇ -mercaptoethanol, 1, 2, 5, 8, 10, 12, 15, 18 or 20 ng/ml of recombinant human basic fibroblast growth factor (b-FGF, Peprotech) , 1 part by volume of a non-essential amino acid aqueous solution (11140, Gibco), 10 parts by volume of Knockout FBS serum replacement (10828-028, Gibco), 89 parts by volume of a-MEM.
  • b-FGF human basic fibroblast growth factor
  • Example 1 cells were seeded at the same density with the same cell source, and 15 mL of TME medium was added. Two hours after the inoculation, the cells were observed to adhere to the cells, and the culture was continued. After about 4 hours of inoculation, the cells were completely adhered, and 15 mL of the test medium was replaced. Observe the growth of the cells.
  • TME medium 0.1 part by volume of ⁇ -mercaptoethanol, 1 part by volume of an aqueous solution of non-essential amino acids (11140, Gibco), 99 parts by volume of a-MEM.
  • the third generation of hUC-MSC isolated from the natural umbilical cord of the newborn baby was inoculated into the T75 cell culture flask at a density of 2 ⁇ 10 4 cells/cm 2 and cultured with 15 mL of TME.
  • the base was transferred to a 37 ° C incubator with a CO 2 concentration of 5%.
  • Two hours after the inoculation the cells were attached to the antennae, and the cells were removed from the incubator at 24 hours and 48 hours. The cells were in good condition, but a large number of floating dead cells appeared.
  • the proliferation was not obvious; on the third day after inoculation, the fresh ME medium was replaced and the culture was continued, and the cells gradually fell off from the bottom of the bottle and the proliferation was not obvious.
  • TMD medium 0.1 part by volume of ⁇ -mercaptoethanol, 10 ng/ml of recombinant human basic fibroblast growth factor (b-FGF, Peprotech), 1 part by volume of aqueous solution of non-essential amino acids (11140, Gibco), 10 Volume fraction of Knockout FBS serum replacement (10828-028, Gibco), 89 parts by volume of a-MEM
  • Example 4 cells were seeded at the same density with the same cell source, and 15 mL of TMD medium was added. Similarly, after 2 hours of inoculation, cell adhesion was observed, and hUC-MSC still remained. A large number of cells floated unattached; cells were observed after 24 hours, cell adherence was uneven, local aggregation; after 48 hours, hUC-MSC cells adhered to a larger area of aggregation; on the third day after inoculation, fresh TMD culture was replaced. The cells continued to culture, some of the cells fell off during the liquid exchange process, and a small number of cells died of local aging. After 96 hours of culture, the cell confluence was about 90%.
  • Example 6 Serum-free stepwise culture of hUC-MSC using the kit of the present invention
  • TME medium 0.1 part by volume of ⁇ -mercaptoethanol, 1 part by volume of an aqueous solution of non-essential amino acids (11140, Gibco), 99 parts by volume of a-MEM;
  • TMD medium 0.1 part by volume of ⁇ -mercaptoethanol, 10 ng/ml of recombinant human basic fibroblast growth factor (b-FGF, Peprotech), 1 part by volume of aqueous solution of non-essential amino acids (11140, Gibco), 10 Volume fraction of Knockout FBS serum replacement (10828-028, Gibco), 89 parts by volume of a-MEM.
  • Example 4 cells were seeded at the same density with the same cell source, and 15 mL of TME medium was added. After 2 hours of inoculation, the cells were observed to adhere to the culture, and the culture was continued. After about 4 hours of inoculation, the cells were completely adherent, and the fresh TMD medium was replaced. After 24 hours of inoculation, the cells were observed, and hUC-MSCs were fusiformly vortex-likely aggregated. High, cells are bright, confluence is 40-60%; cells are observed 48 hours after inoculation, hUC-MSC cells are bright, more than 90% confluence, and cells are cryopreserved by trypsin digestion.
  • the cells were not rolled up and left to maintain a good adherence for a long time.
  • Example 6 Comparing Example 6 with Example 1, it can be seen that the present invention adopts TME medium and TMD medium for serum-free stepwise culture, and achieves the same results as conventional serum culture, but at the same time avoids introduction in cultured cells. Serum causes the risk of spreading heterologous pathogens, and also avoids the instability of cell growth due to differences in serum batches during culture.
  • Example 6 The passage 3 cells cultured in Example 6 were taken, and after the cells were grown to 90% confluence, 2 mL of 0.125% trypsin was digested, and then centrifuged at 1200 rpm for 6 minutes at 4 ° C, the supernatant was discarded, and the cells were washed twice, and the cells were washed twice.
  • Example 8 Cell viability analyzer for analyzing cell viability and growth characteristics of hUC-MSC
  • Example 6 The passage 3 cells cultured in Example 6 were inoculated into a T25 flask, and after the cells reached 95%-100% confluence, 0.125% trypsinization was performed, and the collected cells were seeded at a density of 1 ⁇ 10 5 /well in two 6 Orifice plate. After the cells were all adherent and partially grown for 10 hours, two wells of cells were collected and 500 ⁇ L of PBS was used to prepare a cell suspension, which was analyzed by a cell analysis (cell viability analyzer Vi-Cell XR, Beckman). Samples were taken every 12 hours thereafter and growth curves were plotted.
  • a cell analysis cell viability analyzer Vi-Cell XR, Beckman
  • the 3rd generation hUC-MSC cultured in Example 6 was inoculated to a 6-well cell culture plate at 3 ⁇ 10 4 cells/cm 2 , and 24 hours later, freshly prepared human UC MSC osteogenic differentiation medium was added per well ( HUXUC-90021, Saiye product) 2mL, after which every 3 days to replace the fresh osteogenic differentiation induction medium, 2 weeks after the paraformaldehyde fixation, alizarin red staining 3-5min.
  • Fig. 8A shows that after two weeks of osteogenic induction, the hUC-MSC obtained by the method of the present invention has a deep red color reaction with the calcium nodules of the alizarin red and the osteogenesis process.
  • the 3rd generation hUC-MSC cultured in Example 6 was inoculated into a 6-well cell culture plate at 2 ⁇ 10 4 cells/cm 2 , and after the cells reached 100% confluence, the adipogenic differentiation medium A was added to each well ( HUXUC-90031, the Saiye product) began to induce, and after 3 days, it was replaced with the adipogenic differentiation medium B for 24 hours, and thus circulated.
  • Fig. 8B shows that the hUC-MSC obtained by the method of the present invention stains the adipogenic cells significantly after two weeks of adipogenic induction.
  • the 5th generation hUC-MSC cultured in Example 6 was inoculated into a 24-well cell culture plate at a density of 5 ⁇ 10 3 cells per well, and the cells were grown to 30% to 50% confluence and fixed with 4% paraformaldehyde. After minute, it was perforated with 0.25% TritonX-100 for 20 minutes, and the goat serum was blocked and then diluted with anti-human primary antibody (anti-SOX2 antibody, anti-OCT4 antibody, anti-NANOG antibody and anti-NANOG antibody).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un procédé de culture sans sérum pour cellules souches mésenchymateuses de cordon ombilical humain (hUC-MSC), ledit procédé utilisant un procédé étape par étape de culture de hUC-MSC qui comprend les étapes qui consistent à : d'abord utiliser un milieu de culture TME pour une mise en culture pendant 3-4 heures afin de favoriser l'adhérence des hUC-MSC, puis à passer à un milieu de culture TMD pour l'amplification rapide.
PCT/CN2015/097150 2015-12-11 2015-12-11 Trousse de réactif pour culture étape par étape de huc-msc et huc-msc acquises au moyen dudit kit de réactif WO2017096617A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/061,272 US11091739B2 (en) 2015-12-11 2015-12-11 Reagent kit for step-by-step hUC-MSC culture and hUC-MSC acquired using said reagent kit
PCT/CN2015/097150 WO2017096617A1 (fr) 2015-12-11 2015-12-11 Trousse de réactif pour culture étape par étape de huc-msc et huc-msc acquises au moyen dudit kit de réactif

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/097150 WO2017096617A1 (fr) 2015-12-11 2015-12-11 Trousse de réactif pour culture étape par étape de huc-msc et huc-msc acquises au moyen dudit kit de réactif

Publications (1)

Publication Number Publication Date
WO2017096617A1 true WO2017096617A1 (fr) 2017-06-15

Family

ID=59013663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/097150 WO2017096617A1 (fr) 2015-12-11 2015-12-11 Trousse de réactif pour culture étape par étape de huc-msc et huc-msc acquises au moyen dudit kit de réactif

Country Status (2)

Country Link
US (1) US11091739B2 (fr)
WO (1) WO2017096617A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11254915B2 (en) 2015-12-11 2022-02-22 Lei Guo Method for separating and culturing mesenchymal stem cells from Wharton's jelly tissue of umbilical cord

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2713062T3 (es) 2005-09-27 2019-05-17 Tissuetech Inc Preparaciones de membrana amniótica y composiciones purificadas y métodos de uso
CN114652816A (zh) 2012-07-11 2022-06-24 组织技术公司 含有hc-ha/ptx3复合物的组合物及其使用方法
TW201642914A (zh) 2015-02-23 2016-12-16 組織科技股份有限公司 用於治療眼部疾病及失調的裝置及方法
WO2016187555A1 (fr) 2015-05-20 2016-11-24 Tissuetech, Inc. Compositions et procédés pour la prévention de la prolifération et de la transition épithélio-mésenchymateuse des cellules épithéliales
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
CN110295141A (zh) * 2019-06-11 2019-10-01 华夏源（上海）细胞基因工程股份有限公司 一种脐带间充质干细胞的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018307A1 (fr) * 2010-08-05 2012-02-09 Agency For Science, Technology And Research Substrats fibreux pour la propagation et la différenciation cellulaires
CN102559590A (zh) * 2012-01-16 2012-07-11 遵义医学院附属医院 用两种培养基序贯培养人脐带血间充质干细胞的方法
US20130302285A1 (en) * 2011-11-09 2013-11-14 National University Of Singapore Wharton's Jelly Mesenchymal Stem Cells and Uses Thereof
CN103805562A (zh) * 2014-01-13 2014-05-21 章毅 培养胎盘间充质干细胞的无血清培养基

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313535B1 (ko) * 2011-04-26 2013-10-01 차의과학대학교 산학협력단 인간 배아줄기세포 또는 역분화 만능줄기세포의 줄기세포성 유지용 배지 및 이를 이용한 배양방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018307A1 (fr) * 2010-08-05 2012-02-09 Agency For Science, Technology And Research Substrats fibreux pour la propagation et la différenciation cellulaires
US20130302285A1 (en) * 2011-11-09 2013-11-14 National University Of Singapore Wharton's Jelly Mesenchymal Stem Cells and Uses Thereof
CN102559590A (zh) * 2012-01-16 2012-07-11 遵义医学院附属医院 用两种培养基序贯培养人脐带血间充质干细胞的方法
CN103805562A (zh) * 2014-01-13 2014-05-21 章毅 培养胎盘间充质干细胞的无血清培养基

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIKRAM, S. ET AL.: "Human Wharton's Jelly Mesenchymal Stem Cells Plasticity Augments Scar-Free Skin Wound Healing with Hair Growth", PLOS ONE, vol. 9, no. 4, 15 April 2014 (2014-04-15), pages 1 - 10, XP055389275, ISSN: 1932-6203 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11254915B2 (en) 2015-12-11 2022-02-22 Lei Guo Method for separating and culturing mesenchymal stem cells from Wharton's jelly tissue of umbilical cord

Also Published As

Publication number Publication date
US20180362932A1 (en) 2018-12-20
US11091739B2 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
WO2017096617A1 (fr) Trousse de réactif pour culture étape par étape de huc-msc et huc-msc acquises au moyen dudit kit de réactif
WO2017096607A1 (fr) Procédé de séparation et d'extraction de huc-msc d'une couche externe de tissu de membrane amniotique du cordon ombilical
US11254915B2 (en) Method for separating and culturing mesenchymal stem cells from Wharton's jelly tissue of umbilical cord
WO2017096615A1 (fr) Procédé de séparation et d'extraction de csm-coh de cordon ombilical humain à partir de tissu de gelée de wharton de cordon ombilical
WO2017096616A1 (fr) Milieu de culture sans sérum et procédé de préparation et application correspondants
WO2017096618A1 (fr) Procédé de séparation et de culture de cellules souches mésenchymateuses de la couche externe de la membrane amniotique du cordon ombilical
Iacono et al. Isolation, characterization and differentiation of mesenchymal stem cells from amniotic fluid, umbilical cord blood and Wharton's jelly in the horse
CN103154241B (zh) 用于培养羊膜来源间充质干细胞的培养基组合物和用其培养羊膜来源间充质干细胞的方法
KR100908481B1 (ko) 중간엽 줄기세포 배양 배지 및 이를 이용한 중간엽줄기세포의 배양 방법
WO2016049986A1 (fr) Procédé de séparation de cellules souches mésenchymateuses de cordon ombilical
US20110312091A1 (en) Pluripotent stem cells, method for preparation thereof and uses thereof
CN105420183A (zh) 一种从脐带华通氏胶组织中分离培养脐带间充质干细胞的方法
CN105420184A (zh) 一种从脐带外层羊膜组织中分离培养脐带间充质干细胞的方法
CN105420189A (zh) 一种无血清培养基及其制备方法和用途
CN107418930A (zh) 一种纯化与扩增人骨髓间充质干细胞的制备方法
Hassan et al. Isolation of umbilical cord mesenchymal stem cells using human blood derivatives accompanied with explant method
KR101175175B1 (ko) 인간 줄기세포에서 고활성 줄기세포를 분리하는 방법 및상기 방법에 의해 분리된 고활성 줄기 세포
CN108504628A (zh) 人脐带间充质干细胞的培养方法
CN106119191A (zh) 一种胎盘绒毛板间充质干细胞及临床化制备方法
CN105420185A (zh) 一种从脐带外层羊膜组织中分离提取hUC-MSC的方法
CN105420187B (zh) 一种用于分步培养hUC-MSC的试剂盒及采用所述试剂盒获得的hUC-MSC
WO2017096610A1 (fr) Procédé de culture de csm coh par étape et sans sérum et csm coh acquises à l'aide dudit procédé
CN105420186A (zh) 一种用于培养细胞的试剂盒
CN108753710A (zh) 一种无血清完全培养基及其应用
WO2017096619A1 (fr) Kit de réactifs pour culture cellulaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15910091

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15910091

Country of ref document: EP

Kind code of ref document: A1